Watch-and-wait safe for rectal tumors beyond exam reach

Watch-and-wait management is viable for rectal cancers not palpable on exam, keeping patient outcomes comparable.

3-year local regrowth-free survival rates: 81.4% for palpable vs. 74.3% for nonpalpable tumors.
3-year disease-free survival rates: 80.8% for palpable vs. 74.3% for nonpalpable tumors.

Surgeons can confidently consider watch-and-wait for these cases without compromising efficacy.

Initial clinical responses don’t significantly affect long-term outcomes, but delayed responses may indicate faster risks for recurrence and organ loss.

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Intestine and Lower Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

More in Intestine and Lower Gastrointestinal Tract

Ann Surg Oncol2 Nov 2026

Patients smoking at diagnosis were less likely to have a favorable response to treatment before rectal cancer surgery; former smokers were not.

JAMA Surg30 Oct 2026

For severe slow-transit constipation, removing less colon gave similar symptom relief at one year, with less early incontinence.

Surg Endosc29 Oct 2026

In low rectal cancer surgery, removing the specimen through the anus was linked to fewer wound complications and less pain in the first two days.